A
786.32
4.60 (0.59%)
| Previous Close | 781.72 |
| Open | 782.06 |
| Volume | 116,570 |
| Avg. Volume (3M) | 343,879 |
| Market Cap | 49,141,043,200 |
| Price / Earnings (TTM) | 40.26 |
| Price / Earnings (Forward) | 29.50 |
| Price / Sales | 11.11 |
| Price / Book | 6.64 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 40.26% |
| Operating Margin (TTM) | 17.50% |
| Diluted EPS (TTM) | 16.39 |
| Quarterly Revenue Growth (YOY) | 95.70% |
| Total Debt/Equity (MRQ) | 0.71% |
| Current Ratio (MRQ) | 7.29 |
| Operating Cash Flow (TTM) | -82.75 M |
| Levered Free Cash Flow (TTM) | -143.39 M |
| Return on Assets (TTM) | -0.21% |
| Return on Equity (TTM) | 17.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | argenx SE | Bearish | Bullish |
AIStockmoo Score
0.1
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -1.0 |
| Average | 0.13 |
|
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Institutions | 55.54% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,247.00 (Wells Fargo, 58.59%) | Buy |
| Median | 944.00 (20.05%) | |
| Low | 867.00 (Baird, 10.26%) | Hold |
| Average | 1,001.14 (27.32%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 763.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wedbush | 09 Mar 2026 | 1,000.00 (27.17%) | Buy | 740.40 |
| Baird | 27 Feb 2026 | 867.00 (10.26%) | Hold | 766.92 |
| Citizens | 27 Feb 2026 | 944.00 (20.05%) | Buy | 766.92 |
| Guggenheim | 27 Feb 2026 | 1,120.00 (42.44%) | Buy | 766.92 |
| HC Wainwright & Co. | 27 Feb 2026 | 940.00 (19.54%) | Buy | 766.92 |
| RBC Capital | 27 Feb 2026 | 890.00 (13.19%) | Buy | 766.92 |
| Wells Fargo | 27 Feb 2026 | 1,247.00 (58.59%) | Buy | 766.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |